Can targeting lipid metabolism improve treatment of SDH-deficient gastrointestinal stromal tumors? This phase 1b study reports promising activity of olverembatinib, which suppresses CD36 expression and lipid uptake.

#STTT #OpenAccess: doi.org/10.1038/s413...
#CancerMetabolism #LipidUptake